Because SARS-CoV-2 transmission was a major concern during the Tokyo 2020 Olympic and Paralympic Games, wastewater surveillance,1 mandatory daily screenings with antigen saliva tests,2 and polymerase chain reaction (PCR) tests for close contacts of individuals with confirmed cases3 were conducted in the Olympic and Paralympic Village. In this cross-sectional study, we investigated the association of SARS-CoV-2 load in wastewater with the numbers of confirmed COVID-19 cases and tests for close contacts.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: June 27, 2022.
Published: August 22, 2022. doi:10.1001/jamanetworkopen.2022.26822
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Kitajima M et al. JAMA Network Open.
Corresponding Author: Masaaki Kitajima, PhD, Division of Environmental Engineering, Faculty of Engineering, Hokkaido University, North 13 West 8, Kita-ku, Sapporo, Hokkaido 060-8628, Japan (email@example.com).
Author Contributions: Drs Kitajima and Imoto had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Kitajima, Murakami, Katayama, Imoto.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Kitajima, Imoto.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Kitajima, Murakami, Imoto.
Obtained funding: Kitajima, Katayama.
Administrative, technical, or material support: Kitajima, Murakami, Kadoya, Kuroita, Katayama, Imoto.
Supervision: Kitajima, Imoto.
Conflict of Interest Disclosures: Dr Kitajima reported receiving grants from Shionogi & Co Ltd during the conduct of the study and having a pending patent for method for nucleic acid detection and quantification from environmental samples with royalties paid from Shionogi & Co Ltd. Dr Imoto reported receiving grants from Astellas Pharma, Daiichi Sankyo RD Novare, Fujitsu Ltd, Shiseido Co, BrightPath Biotherapeutics Co Ltd, and Liquid Mine and serving on the scientific advisory board for Axial Therapeutics, Inc outside the submitted work. No other disclosures were reported.
Additional Contributions: Satoshi Okabe, PhD (Hokkaido University) and Hiroyuki Kobayashi, PhD, Ryo Iwamoto, MS, and Tomoyuki Ohkawa, PhD (Shionogi & Co Ltd) provided supervision. Kiyoshi Yamaguchi, PhD, Kotoe Katayama, PhD, Shoji Karasawa, and Miwako Nakagawa MS, (The University of Tokyo); Daiki Goto, BS (Hokkaido University); and Tatsuya Ikehara, PhD, Masato Wakabayashi, PhD, Yu Tsurekawa, PhD, Kazuki Akazawa, PhD, Kenji Kikushima, BS, and Daiki Murakami, BS (Shionogi & Co Ltd) assisted with sample collection and analysis. These individuals were not compensated.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.